1.71
price down icon6.56%   -0.12
after-market After Hours: 1.84 0.13 +7.60%
loading
Citius Oncology Inc stock is traded at $1.71, with a volume of 167.64K. It is down -6.56% in the last 24 hours and down -8.56% over the past month. Citius Oncology Inc is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products targeting unmet needs with a focus on oncology products. In addition, Citius completed enrollment in its Phase 2b trial of CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids.
See More
Previous Close:
$1.83
Open:
$1.85
24h Volume:
167.64K
Relative Volume:
0.27
Market Cap:
$134.01M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-9.52%
1M Performance:
-8.56%
6M Performance:
+176.21%
1Y Performance:
+76.29%
1-Day Range:
Value
$1.70
$1.85
1-Week Range:
Value
$1.70
$1.93
52-Week Range:
Value
$0.5506
$6.19

Citius Oncology Inc Stock (CTOR) Company Profile

Name
Name
Citius Oncology Inc
Name
Phone
(908) 967-6677
Name
Address
11 COMMERCE DRIVE, CRANFORD
Name
Employee
0
Name
Twitter
Name
Next Earnings Date
Name
Latest SEC Filings
Name
CTOR's Discussions on Twitter

Compare CTOR with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Drug Manufacturers - Specialty & Generic icon
CTOR
Citius Oncology Inc
1.71 152.83M 0 0 0 0.00
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
141.11 63.55B 9.39B 2.62B 2.22B 5.8121
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
13.71 44.47B 29.96B 957.25M 4.77B 0.2956
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
9.00 40.17B 14.26B 1.98B 2.47B 0.4327
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
20.03 22.99B 16.70B -157.13M 1.19B -0.1446
Drug Manufacturers - Specialty & Generic icon
UTHR
United Therapeutics Corp
440.00 20.14B 3.08B 1.24B 1.07B 25.61

Citius Oncology Inc Stock (CTOR) Upgrades & Downgrades

Date Action Analyst Rating Change
Sep-23-25 Upgrade Maxim Group Hold → Buy
Nov-27-24 Initiated Maxim Group Buy

Citius Oncology Inc Stock (CTOR) Latest News

pulisher
10:49 AM

Is Citius Oncology Inc. a candidate for recovery playStock Surge & Safe Swing Trade Setup Alerts - newser.com

10:49 AM
pulisher
10:49 AM

Sector ETF performance correlation with Citius Oncology Inc.July 2025 Rallies & Safe Swing Trade Setup Alerts - newser.com

10:49 AM
pulisher
07:14 AM

Is Citius Oncology Inc. stock bottoming outOil Prices & Target Return Focused Stock Picks - newser.com

07:14 AM
pulisher
05:48 AM

Heatmap analysis for Citius Oncology Inc. and competitorsMarket Sentiment Summary & Precise Swing Trade Alerts - newser.com

05:48 AM
pulisher
02:48 AM

Why Citius Oncology Inc. stock is recommended by analystsJuly 2025 Summary & Verified Technical Signals - newser.com

02:48 AM
pulisher
Oct 09, 2025

Citius Oncology's (CTOR) "Sell (D-)" Rating Reaffirmed at Weiss Ratings - MarketBeat

Oct 09, 2025
pulisher
Oct 09, 2025

How Citius Oncology Inc. stock benefits from tech adoptionWeekly Stock Summary & Long-Term Growth Stock Strategies - newser.com

Oct 09, 2025
pulisher
Oct 09, 2025

How Citius Oncology Inc. stock performs in stagflationTrade Risk Summary & Low Drawdown Trading Strategies - newser.com

Oct 09, 2025
pulisher
Oct 09, 2025

What to do if you’re stuck in Citius Oncology Inc.2025 Support & Resistance & Weekly Momentum Picks - newser.com

Oct 09, 2025
pulisher
Oct 09, 2025

Will a bounce in Citius Oncology Inc. offer an exitMarket Movement Recap & Safe Entry Zone Identification - newser.com

Oct 09, 2025
pulisher
Oct 09, 2025

Has Citius Oncology Inc. formed a bullish divergenceVolume Spike & Daily Volume Surge Signals - newser.com

Oct 09, 2025
pulisher
Oct 09, 2025

Is it time to cut losses on Citius Oncology Inc.Trade Volume Report & Real-Time Stock Price Movement Reports - newser.com

Oct 09, 2025
pulisher
Oct 08, 2025

Citius in talks over Lymphir access in global markets - The Pharma Letter

Oct 08, 2025
pulisher
Oct 07, 2025

Citius Sets Up Access to Lymphir in Southern Europe - MarketScreener

Oct 07, 2025
pulisher
Oct 07, 2025

Citius Oncology expands LYMPHIR access through named patient programs - Investing.com

Oct 07, 2025
pulisher
Oct 07, 2025

Citius Oncology enters exclusive distribution agreement with Integris Pharma S.A. - MarketScreener

Oct 07, 2025
pulisher
Oct 07, 2025

Citius Oncology Establishes International Access to LYMPHIR™ via Named Patient Programs in Southern Europe - PR Newswire

Oct 07, 2025
pulisher
Oct 06, 2025

Citius Oncology, Inc. (NASDAQ:CTOR) Sees Significant Decline in Short Interest - Defense World

Oct 06, 2025
pulisher
Oct 05, 2025

Is a relief rally coming for Citius Oncology Inc. holdersWeekly Stock Analysis & AI Enhanced Market Trend Forecasts - newser.com

Oct 05, 2025
pulisher
Oct 05, 2025

Is it too late to sell Citius Oncology Inc.July 2025 Final Week & High Yield Stock Recommendations - newser.com

Oct 05, 2025
pulisher
Oct 05, 2025

Can volume confirm reversal in Citius Oncology Inc.July 2025 Highlights & Low Risk Entry Point Tips - newser.com

Oct 05, 2025
pulisher
Oct 05, 2025

Using data tools to time your Citius Oncology Inc. exit2025 Earnings Impact & Technical Analysis for Trade Confirmation - newser.com

Oct 05, 2025
pulisher
Oct 05, 2025

What MACD and RSI say about Citius Oncology Inc.Trade Risk Report & Long-Term Safe Return Strategies - newser.com

Oct 05, 2025
pulisher
Oct 03, 2025

Citius Oncology, Inc. (NASDAQ:CTOR) Short Interest Down 55.2% in September - MarketBeat

Oct 03, 2025
pulisher
Oct 03, 2025

Citius Oncology (NASDAQ:CTOR) and Structure Therapeutics (NASDAQ:GPCR) Head to Head Survey - Defense World

Oct 03, 2025
pulisher
Sep 30, 2025

Citius Oncology (CTOR) Price Target Increased by 100.00% to 6.12 - Nasdaq

Sep 30, 2025

Citius Oncology Inc Stock (CTOR) Financials Data

There is no financial data for Citius Oncology Inc (CTOR). Check out other stocks for more information.

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$19.76
price down icon 1.54%
$9.74
price down icon 2.50%
$53.95
price down icon 7.38%
drug_manufacturers_specialty_generic RDY
$14.34
price up icon 1.20%
$136.63
price down icon 1.33%
$440.00
price down icon 1.21%
Cap:     |  Volume (24h):